{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:41:57Z","timestamp":1789684917447,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacl.2025.09.014","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T23:37:51Z","timestamp":1758152271000},"page":"1575-1585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Meta-analysis of the impact of statins on change in renal function in patients with moderate or severe chronic kidney disease"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8637-9549","authenticated-orcid":false,"given":"Deepak","family":"Vedamurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Sagheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6035-3876","authenticated-orcid":false,"given":"Mahima","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-5469","authenticated-orcid":false,"given":"Kevin C.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-4067","authenticated-orcid":false,"given":"Dinesh K.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4S","key":"10.1016\/j.jacl.2025.09.014_bib0001","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2025.09.014_bib0002","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease. Statistics for the United States. National Institutes of Health, U.S. Department of Health and Human Services. Accessed January 01, 2025 https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/kidney-disease."},{"issue":"10225","key":"10.1016\/j.jacl.2025.09.014_bib0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.jacl.2025.09.014_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/TP.0b013e3181caeead","article-title":"Reduction in cardiovascular death after kidney transplantation","volume":"89","author":"Pilmore","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2025.09.014_bib0005","series-title":"2024 USRDS Annual Data report: Epidemiology of kidney disease in the United States","year":"2024"},{"issue":"11","key":"10.1016\/j.jacl.2025.09.014_bib0006","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jacl.2025.09.014_bib0007","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2025.09.014_bib0008","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacl.2025.09.014_bib0009","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.34067\/KID.0000000000000212","article-title":"Health care costs associated with the development and combination of cardio-renal-metabolic diseases","volume":"4","author":"Nichols","year":"2023","journal-title":"Kidney360"},{"issue":"2","key":"10.1016\/j.jacl.2025.09.014_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2023.04.052","article-title":"Cardiovascular outcomes in patients with diabetes and kidney disease: JACC review topic of the week","volume":"82","author":"Morales","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.09.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102615","article-title":"Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study","volume":"72","author":"Chadban","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0012","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/ATVBAHA.112.300624","article-title":"Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: the Multi-Ethnic Study of Atherosclerosis","volume":"33","author":"Lamprea-Montealegre","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"10.1016\/j.jacl.2025.09.014_bib0013","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2025.09.014_bib0014","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.jacl.2025.09.014_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010640","article-title":"Trends in statin use among US adults with chronic kidney disease, 1999-2014","volume":"8","author":"Mefford","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12170-025-00763-y","article-title":"Management of dyslipidemia in chronic kidney disease","volume":"19","author":"Vedamurthy","year":"2025","journal-title":"Curr. Cardiovasc. Risk Rep"},{"issue":"14","key":"10.1016\/j.jacl.2025.09.014_bib0017","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee","volume":"80","author":"DM","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0018","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12882-024-03664-1","article-title":"Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024","volume":"25","author":"Zac-Varghese","year":"2024","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.jacl.2025.09.014_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173843","article-title":"Longitudinal change in estimated GFR among CKD patients: a 10-year follow-up study of an integrated kidney disease care program in Taiwan","volume":"12","author":"Tsai","year":"2017","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.jacl.2025.09.014_bib0020","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: a meta-analysis","volume":"17","author":"Sandhu","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.jacl.2025.09.014_bib0021","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53064-x","article-title":"Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis","volume":"9","author":"Esmeijer","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jacl.2025.09.014_bib0023","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.amjcard.2014.05.033","article-title":"Meta-analysis of the effect of statins on renal function","volume":"114","author":"Geng","year":"2014","journal-title":"Am J Cardiol"},{"issue":"7645","key":"10.1016\/j.jacl.2025.09.014_bib0024","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","article-title":"Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials","volume":"336","author":"Strippoli","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jacl.2025.09.014_bib0025","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: a meta-analysis","volume":"17","author":"Sandhu","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.jacl.2025.09.014_bib0026","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53064-x","article-title":"Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis","volume":"9","author":"Esmeijer","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.jacl.2025.09.014_bib0028","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/clc.23923","volume":"45","author":"Shaik","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2025.09.014_bib0029","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. Available from www.Handbook.Cochrane.Org.; 2008. http:\/\/www.cochrane-handbook.org.","DOI":"10.1002\/9780470712184"},{"issue":"5","key":"10.1016\/j.jacl.2025.09.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216559","article-title":"Predicting kidney failure from longitudinal kidney function trajectory: a comparison of models","volume":"14","author":"van den Brand","year":"2019","journal-title":"PloS One"},{"issue":"7414","key":"10.1016\/j.jacl.2025.09.014_bib0031","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.jacl.2025.09.014_bib0032","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jacl.2025.09.014_bib0033","first-page":"153","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"BMJ Ment Health"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease","volume":"44","author":"Fassett","year":"2010","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2010.07.053","article-title":"Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial","volume":"213","author":"Fassett","year":"2010","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacl.2025.09.014_bib0036","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1161\/STROKEAHA.114.005832","article-title":"Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial","volume":"45","author":"Amarenco","year":"2014","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0037","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.jacl.2025.09.014_bib0038","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0039","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2009.09.020","article-title":"Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"55","author":"Kendrick","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0040","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10157-016-1304-6","article-title":"Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial","volume":"21","author":"Kimura","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.jacl.2025.09.014_bib0041","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","article-title":"Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD","volume":"53","author":"Koren","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN107630","article-title":"Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a Pilot Study","volume":"80","author":"Lemos","year":"2013","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1016\/j.jacl.2025.09.014_bib0043","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.atherosclerosis.2009.03.031","article-title":"Pravastatin and cardiovascular risk in moderate chronic kidney disease","volume":"206","author":"Nakamura","year":"2009","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.jacl.2025.09.014_bib0044","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/archinte.167.12.1262","volume":"167","author":"Nanayakkara","year":"2007","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.ajkd.2008.05.027","volume":"52","author":"Rahman","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.jacl.2025.09.014_bib0046","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.104.517565","article-title":"Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0047","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2008.11.010","article-title":"Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"205","author":"Huskey","year":"2009","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.jacl.2025.09.014_bib0048","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0049","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.jacl.2025.09.014_bib0050","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.0000000000000323","article-title":"Cardiovascular-kidney-metabolic health syndrome: what does the American Heart Association framework mean for nephrology?","volume":"35","author":"Bansal","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.jacl.2025.09.014_bib0051","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacl.2025.09.014_bib0052","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0053","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ki.2013.181","article-title":"LDL cholesterol in CKD\u2014to treat or not to treat?","volume":"84","author":"Massy","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0054","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34632-z","article-title":"Effect of statins on renal function in chronic kidney disease patients","volume":"8","author":"Hu","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jacl.2025.09.014_bib0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.jacl.2025.09.014_bib0056","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0057","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jdi.12296","article-title":"Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy","volume":"6","author":"Takazakura","year":"2015","journal-title":"J Diabetes Investig"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.014_bib0058","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"German Diabetes and dialysis Study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jacl.2025.09.014_bib0059","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:37:01Z","timestamp":1780472221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425004003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1933287425004003"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.09.014","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of the impact of statins on change in renal function in patients with moderate or severe chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}